A detailed history of Summit Financial, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Summit Financial, LLC holds 16,149 shares of BMY stock, worth $934,704. This represents 0.03% of its overall portfolio holdings.

Number of Shares
16,149
Previous 13,349 20.98%
Holding current value
$934,704
Previous $554,000 50.72%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $111,047 - $144,900
2,800 Added 20.98%
16,149 $835,000
Q2 2024

Jul 31, 2024

BUY
$40.25 - $52.99 $202,618 - $266,751
5,034 Added 60.54%
13,349 $554,000
Q1 2024

Apr 24, 2024

BUY
$47.98 - $54.4 $33,010 - $37,427
688 Added 9.02%
8,315 $450,000
Q4 2023

Feb 05, 2024

SELL
$48.48 - $57.85 $156,541 - $186,797
-3,229 Reduced 29.74%
7,627 $391,000
Q3 2023

Nov 07, 2023

SELL
$57.89 - $64.73 $19,740 - $22,072
-341 Reduced 3.05%
10,856 $630,000
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $34,785 - $38,624
546 Added 5.13%
11,197 $716,000
Q1 2023

May 03, 2023

BUY
$65.71 - $74.53 $1,511 - $1,714
23 Added 0.22%
10,651 $738,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $203,659 - $241,161
-2,974 Reduced 21.86%
10,628 $764,000
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $1,106 - $653,908
8,510 Added 167.12%
13,602 $967 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $171,673 - $189,072
-2,364 Reduced 31.71%
5,092 $392,000
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $185,054 - $221,897
3,010 Added 67.7%
7,456 $544,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $44,083 - $51,391
822 Added 22.68%
4,446 $277,000
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $214,432 - $251,179
3,624 New
3,624 $214,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Summit Financial, LLC Portfolio

Follow Summit Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Financial, LLC with notifications on news.